PRZOOM - /newswire/ -
Irvine, CA, United States, 2011/08/30 - ChromaDex® signs agreement with the Association for African Medicinal Plants Standards to market botanical reference standards and African Herbal Pharmacopoeia Globally - ChromaDex.com. OTCBB: CDXC
ChromaDex® Corporation, a world leader in phytochemical reference standards, botanical reference materials and contract analytical testing services, has signed an exclusive marketing agreement with the Association for African Medicinal Plants Standards (AAMPS) to sell and market the AAMPS African botanical standards and the African Herbal Pharmacopoeia. The pharmacopoeia provides comprehensive botanical, commercial and phytochemical informational monographs on over fifty of the most important African medicinal plants.
“At AAMPS, we are truly pleased to have ChromaDex® as our marketing partner. Through the efforts of AAMPS, the African botanical community has come together and produced a remarkable set of monographs. The relationship with ChromaDex® will enable us to spread the word about the exciting properties of these amazing African botanical materials,” said Denzil Phillips, Director, AAMPS.
“ChromaDex® is at the forefront in providing comprehensive libraries of phytochemical and botanical standards. We are committed to providing the dietary supplement industry with the tools needed to support critical regulatory and research activities,” stated Frank Jaksch, CEO and co-founder of ChromaDex®. “This collaboration with AAMPS will provide the industry with access to these important materials referencing African botanicals.”
About the Association for African Medicinal Plants Standards
AAMPS is a non-profit company registered in Mauritius dedicated to the development of quality control and quality assurance standards for African medicinal plants and herbal products.
ChromaDex® (chromadex.com) is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. The company has an impressive pipeline of new ingredients, including its pTeroPure® pterostilbene for which it has worldwide, exclusive patent rights.
Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company’s Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.
ChromaDex® Investor Inquiries:
Liviakis Financial Communications, Inc.
John M. Liviakis, President
P: 415-389-4670 - E: John[.]Liviakis.com.
Chandler Chicco Agency
Kerry Sinclair, Media Specialist
P: 310-309-1031 - E: ksinclair[.]ccapr.com.